世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

バイオシミラーに関する市場調査。製品価格の下落が市場成長を補う


Market Study on Biosimilars: Falling Product Prices to Supplement Market Growth

バイオシミラー市場レポート範囲 世界のバイオシミラー市場に関するPersistence Market Researchの最新市場レポートは、機会や現在の市場シナリオを評価し、2022年から2032年の予測期間において市場に関わる対... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Persistence Market Research
パーシスタンスマーケットリサーチ
2022年9月15日 US$4,900
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
250 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

バイオシミラー市場レポート範囲

世界のバイオシミラー市場に関するPersistence Market Researchの最新市場レポートは、機会や現在の市場シナリオを評価し、2022年から2032年の予測期間において市場に関わる対応するセグメントについての洞察や最新情報を提供します。主要な市場力学の詳細な評価や、市場構造に関する包括的な情報を提供しています。2022-2032年の予測期間中に市場がどのように成長すると予想されるかについての詳細な洞察が含まれています。

本レポートの主な目的は、バイオシミラーに関連するグローバルビジネスの変革を支えている市場の機会に関する洞察を提供することです。常に変動する経済において、読者が市場の分析と評価をより良く理解し、この空間における有利な機会を発見できるように、全体的な予測のための複合年間成長率(CAGR)に加えて、推定(Y-oY)対前年成長率を提供するということは非常に重要であると考えています。

また、本レポートでは、市場規模の推定とそれに対応する絶対額での収益予測も行っています。また、市場の将来的な動向に基づいた実用的な洞察も提供しています。さらに、世界のバイオシミラー市場における新規参入企業や新興企業は、本調査で提示された情報を効果的なビジネス上の意思決定に活用することで、自社のビジネスだけでなく世界市場にも勢いを与えることができます。

本調査は、バイオシミラー市場のメーカー、サプライヤー、流通業者、投資家に関連するものです。すべての関係者、業界専門家、研究者、ジャーナリスト、ビジネス研究者は、本レポートに記載された情報とデータを活用することができます。

主な市場セグメント

Persistence Market Research社の調査レポート「世界のバイオシミラー市場」は、製品タイプ、用途、流通チャネル、地域の4つのセグメントに分けて情報を提供しています。

製品タイプ

組換え糖鎖タンパク質
組換え非糖化タンパク質
応用分野

血液学
成長ホルモン欠乏症
腫瘍学
糖尿病 自己免疫疾患
疾患別
その他
販売チャネル

病院薬局
オンライン薬局
小売薬局
地域別

北アメリカ
ラテンアメリカ
欧州
南アジア・太平洋
東アジア
中近東・アフリカ
本調査で回答した主な質問

予測期間中に最も高い市場シェアを占めるのはどの地域か?
最も高い成長(CAGR)を遂げているのはどの地域か?
世界のバイオシミラー産業に影響を及ぼしている要因は何か?
市場に影響を与えている世界的なトレンドは何か?
市場の様々な地域で機会を捉えるために、新興プレイヤーはどのような戦略を採用しなければなりませんか?
世界のバイオシミラー市場の構造はどのようなものか?
研究方法論

Persistence Market Research社は、お客様に偏りのない市場調査ソリューションを提供することに努めています。同社は、本レポートに含まれるデータの控除について、確固たる方法論に従っています。世界のバイオシミラー市場に関する広範な調査を実施し、市場の将来の成長要因に関する結論を得るために、独自の調査方法を利用しています。調査手法は、一次調査手法と二次調査手法の組み合わせで構成されており、本レポートの結論の正確性と信頼性を保証しています。

需要サイドのアプローチで対象製品の売上高を推定し、次に供給サイドのアプローチであらかじめ定義された期間における生成価値、主要トレンド、イベントに関する詳細な評価を行います。

この手法は、Persistence Market Researchが世界市場のセグメント化のために考慮する、北米、中南米、ヨーロッパ、南アジア・太平洋、東アジア、中東・アフリカの6地域以上の現地ソースからのインプットに基づく、標準の市場構造、手法、定義に基づいています。統計、特性、差異を地域レベルで収集し、同じレベルで集計し、世界レベルで統合して、世界市場の測定値を作成しています。

主な調査対象は以下の通りです。

プライマリーリサーチ
セカンダリーリサーチ
貿易調査
ソーシャルメディアリサーチ

ページTOPに戻る


目次

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Technology Roadmap

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Product Adoption / Usage Analysis

4.2. Product USPs / Features

4.3. Strategic Promotional Strategies

5. Global Biosimilars Market Demand Analysis 2017–2021 and Forecast, 2022–2032

5.1. Historical Market Volume (Tons) Analysis, 2017–2021

5.2. Current and Future Market Volume (Tons) Projections, 2022–2032

5.3. Y-o-Y Growth Trend Analysis

6. Global Biosimilars Market - Pricing Analysis

6.1. Regional Pricing Analysis By Product Type

6.2. Global Average Pricing Analysis Benchmark

7. Global Biosimilars Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021

7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Market Background

8.1. Macro-Economic Factors

8.1.1. Global GDP Growth Outlook

8.1.2. Global Industry Value Added Overview

8.1.3. Global Infrastructure Investment Overview

8.1.4. Global Construction Spending Analysis

8.1.5. Other Macro Economic Factors

8.2. Forecast Factors - Relevance & Impact

8.2.1. Top Companies Historical Growth

8.2.2. GDP Growth forecast

8.2.3. Construction Industry forecast

8.2.4. Distribution Channel Growth Outlook

8.2.5. Collaboration Activities

8.3. Value Chain

8.3.1. Raw Material Suppliers

8.3.2. List of Manufacturers

8.3.3. List of Distributors

8.4. COVID-19 Crisis – Impact Assessment

8.4.1. Current Statistics

8.4.2. Short-Mid-Long Term Outlook

8.4.3. Likely Rebound

8.5. Market Dynamics

8.5.1. Drivers

8.5.2. Restraints

8.5.3. Opportunity Analysis

8.5.4. Trends

9. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Product Type

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021

9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Product Type 2022–2032

9.3.1. Recombinant Glycosylated Proteins

9.3.2. Recombinant Non-Glycosylated Proteins

9.4. Market Attractiveness Analysis by Product Type

10. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Application

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021

10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032

10.3.1. Hematology

10.3.2. Growth Hormone Deficiency

10.3.3. Oncology

10.3.4. Diabetes Autoimmune

10.3.5. Disease

10.3.6. Others

10.4. Market Attractiveness Analysis By Application

11. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

11.1. Introduction / Key Findings

11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021

11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032

11.3.1. Hospital Pharmacies

11.3.2. Online Pharmacies

11.3.3. Retail Pharmacies

11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Region

12.1. Introduction

12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021

12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032

12.3.1. North America

12.3.2. Latin America

12.3.3. Europe

12.3.4. East Asia

12.3.5. South Asia and Pacific

12.3.6. Middle East and Africa (MEA)

12.4. Market Attractiveness Analysis By Region

13. North America Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032

13.1. Introduction

13.2. Pricing Analysis

13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032

13.4.1. By Country

13.4.1.1. U.S.

13.4.1.2. Canada

13.4.2. By Type

13.4.3. By Application

13.4.4. By Distribution Channel

13.5. Market Attractiveness Analysis

13.5.1. By Country

13.5.2. By Type

13.5.3. By Application

13.5.4. By Distribution Channel

13.6. Market Trends

13.7. Key Market Participants - Intensity Mapping

13.8. Drivers and Restraints - Impact Analysis

14. Latin America Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

14.1. Introduction

14.2. Pricing Analysis

14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

14.4.1. By Country

14.4.1.1. Brazil

14.4.1.2. Mexico

14.4.1.3. Rest of Latin America

14.4.2. By Type

14.4.3. By Application

14.4.4. By Distribution Channel

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Type

14.5.3. By Application

14.5.4. By Distribution Channel

14.6. Market Trends

14.7. Key Market Participants - Intensity Mapping

14.8. Drivers and Restraints - Impact Analysis

15. Europe Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

15.1. Introduction

15.2. Pricing Analysis

15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021

15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

15.4.1. By Country

15.4.1.1. Germany

15.4.1.2. Italy

15.4.1.3. France

15.4.1.4. U.K.

15.4.1.5. Spain

15.4.1.6. BENELUX

15.4.1.7. Russia

15.4.1.8. Rest of Europe

15.4.2. By Type

15.4.3. By Application

15.4.4. By Distribution Channel

15.5. Market Attractiveness Analysis

15.5.1. By Country

15.5.2. By Type

15.5.3. By Application

15.5.4. By Distribution Channel

15.6. Market Trends

15.7. Key Market Participants - Intensity Mapping

15.8. Drivers and Restraints - Impact Analysis

16. South Asia and Pacific Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

16.1. Introduction

16.2. Pricing Analysis

16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

16.4.1. By Country

16.4.1.1. India

16.4.1.2. ASEAN

16.4.1.3. Oceania

16.4.1.4. Rest of South Asia & Pacific

16.4.2. By Type

16.4.3. By Application

16.4.4. By Distribution Channel

16.5. Market Attractiveness Analysis

16.5.1. By Country

16.5.2. By Type

16.5.3. By Application

16.5.4. By Distribution Channel

16.6. Market Trends

16.7. Key Market Participants - Intensity Mapping

16.8. Drivers and Restraints - Impact Analysis

17. East Asia Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

17.1. Introduction

17.2. Pricing Analysis

17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

17.4.1. By Country

17.4.1.1. China

17.4.1.2. Japan

17.4.1.3. South Korea

17.4.2. By Type

17.4.3. By Application

17.4.4. By Distribution Channel

17.5. Market Attractiveness Analysis

17.5.1. By Country

17.5.2. By Type

17.5.3. By Application

17.5.4. By Distribution Channel

17.6. Market Trends

17.7. Key Market Participants - Intensity Mapping

17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

18.1. Introduction

18.2. Pricing Analysis

18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

18.4.1. By Country

18.4.1.1. GCC Countries

18.4.1.2. Turkey

18.4.1.3. Northern Africa

18.4.1.4. South Africa

18.4.1.5. Rest of Middle East and Africa

18.4.2. By Type

18.4.3. By Application

18.4.4. By Distribution Channel

18.5. Market Attractiveness Analysis

18.5.1. By Country

18.5.2. By Type

18.5.3. By Application

18.5.4. By Distribution Channel

18.6. Market Trends

18.7. Key Market Participants - Intensity Mapping

18.8. Drivers and Restraints - Impact Analysis

19. Emerging Countries Biosimilars Market Analysis

19.1. Introduction

19.1.1. Market Value Proportion Analysis, By Key Countries

19.1.2. Global Vs. Country Growth Comparison

19.2. U.S. Biosimilars Market Analysis

19.2.1. By Type

19.2.2. By Application

19.2.3. By Distribution Channel

19.3. Canada Biosimilars Market Analysis

19.3.1. By Type

19.3.2. By Application

19.3.3. By Distribution Channel

19.4. Mexico Biosimilars Market Analysis

19.4.1. By Type

19.4.2. By Application

19.4.3. By Distribution Channel

19.5. Brazil Biosimilars Market Analysis

19.5.1. By Type

19.5.2. By Application

19.5.3. By Distribution Channel

19.6. Germany Biosimilars Market Analysis

19.6.1. By Type

19.6.2. By Application

19.6.3. By Distribution Channel

19.7. Italy Biosimilars Market Analysis

19.7.1. By Type

19.7.2. By Application

19.7.3. By Distribution Channel

19.8. France Biosimilars Market Analysis

19.8.1. By Type

19.8.2. By Application

19.8.3. By Distribution Channel

19.9. U.K. Biosimilars Market Analysis

19.9.1. By Type

19.9.2. By Application

19.9.3. By Distribution Channel

19.10. Spain Biosimilars Market Analysis

19.10.1. By Type

19.10.2. By Application

19.10.3. By Distribution Channel

19.11. BENELUX Biosimilars Market Analysis

19.11.1. By Type

19.11.2. By Application

19.11.3. By Distribution Channel

19.12. Russia Biosimilars Market Analysis

19.12.1. By Type

19.12.2. By Application

19.12.3. By Distribution Channel

19.13. China Biosimilars Market Analysis

19.13.1. By Type

19.13.2. By Application

19.13.3. By Distribution Channel

19.14. Japan Biosimilars Market Analysis

19.14.1. By Type

19.14.2. By Application

19.14.3. By Distribution Channel

19.15. S. Korea Biosimilars Market Analysis

19.15.1. By Type

19.15.2. By Application

19.15.3. By Distribution Channel

19.16. India Biosimilars Market Analysis

19.16.1. By Type

19.16.2. By Application

19.16.3. By Distribution Channel

19.17. ASEAN Biosimilars Market Analysis

19.17.1. By Type

19.17.2. By Application

19.17.3. By Distribution Channel

19.18. Australia and New Zealand Biosimilars Market Analysis

19.18.1. By Type

19.18.2. By Application

19.18.3. By Distribution Channel

19.19. GCC Countries Biosimilars Market Analysis

19.19.1. By Type

19.19.2. By Application

19.19.3. By Distribution Channel

19.20. Turkey Biosimilars Market Analysis

19.20.1. By Type

19.20.2. By Application

19.20.3. By Distribution Channel

19.21. Northern Africa Biosimilars Market Analysis

19.21.1. By Type

19.21.2. By Application

19.21.3. By Distribution Channel

19.22. South Africa Biosimilars Market Analysis

19.22.1. By Type

19.22.2. By Application

19.22.3. By Distribution Channel

20. Market Structure Analysis

20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)

20.2. Market Share Analysis of Top Players

20.3. Market Presence Analysis

21. Competition Analysis

21.1. Competition Dashboard

21.2. Competition Benchmarking

21.3. Competition Deep Dive

21.3.1. Pfizer Inc.

21.3.1.1. Overview

21.3.1.2. Product Portfolio

21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

21.3.1.4. Sales Footprint

21.3.1.5. Strategy Overview

21.3.2. Sandoz International GMBH

21.3.2.1. Overview

21.3.2.2. Product Portfolio

21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

21.3.2.4. Sales Footprint

21.3.2.5. Strategy Overview

21.3.3. Eli Lily & Company

21.3.3.1. Overview

21.3.3.2. Product Portfolio

21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

21.3.3.4. Sales Footprint

21.3.3.5. Strategy Overview

21.3.4. Hospira Inc.

21.3.4.1. Overview

21.3.4.2. Product Portfolio

21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

21.3.4.4. Sales Footprint

21.3.4.5. Strategy Overview

21.3.5. Amgen, Inc.

21.3.5.1. Overview

21.3.5.2. Product Portfolio

21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

21.3.5.4. Sales Footprint

21.3.5.5. Strategy Overview

21.3.6. Biocon Ltd.

21.3.6.1. Overview

21.3.6.2. Product Portfolio

21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

21.3.6.4. Sales Footprint

21.3.6.5. Strategy Overview

21.3.7. Actavis, Inc.

21.3.7.1. Overview

21.3.7.2. Product Portfolio

21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

21.3.7.4. Sales Footprint

21.3.7.5. Strategy Overview

21.3.8. Cipla Ltd.

21.3.8.1. Overview

21.3.8.2. Product Portfolio

21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

21.3.8.4. Sales Footprint

21.3.8.5. Strategy Overview

21.3.9. Teva Pharmaceutical Industries, Ltd.

21.3.9.1. Overview

21.3.9.2. Product Portfolio

21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

21.3.9.4. Sales Footprint

21.3.9.5. Strategy Overview

21.3.10. Dr. Reddy’s Laboratories Ltd.

21.3.10.1. Overview

21.3.10.2. Product Portfolio

21.3.10.3. Profitability by Market Segments (Product/Channel/Region)

21.3.10.4. Sales Footprint

21.3.10.5. Strategy Overview

21.3.11. Celltrion, Inc.

21.3.11.1. Overview

21.3.11.2. Product Portfolio

21.3.11.3. Profitability by Market Segments (Product/Channel/Region)

21.3.11.4. Sales Footprint

21.3.11.5. Strategy Overview

21.3.12. Stada Arzeimittel Ag

21.3.12.1. Overview

21.3.12.2. Product Portfolio

21.3.12.3. Profitability by Market Segments (Product/Channel/Region)

21.3.12.4. Sales Footprint

21.3.12.5. Strategy Overview

21.3.13. Mylan, Inc.

21.3.13.1. Overview

21.3.13.2. Product Portfolio

21.3.13.3. Profitability by Market Segments (Product/Channel/Region)

21.3.13.4. Sales Footprint

21.3.13.5. Strategy Overview

21.3.14. Wockhardt Ltd.

21.3.14.1. Overview

21.3.14.2. Product Portfolio

21.3.14.3. Profitability by Market Segments (Product/Channel/Region)

21.3.14.4. Sales Footprint

21.3.14.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

 

ページTOPに戻る


 

Summary

Biosimilars Market: Report Scope

The latest market report by Persistence Market Research on the global biosimilars market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides detailed assessment of key market dynamics, and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.

The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with biosimilars. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.

This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on the future trends in the market. Furthermore, new and emerging players in the global biosimilars market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.

The study is relevant for manufacturers, suppliers, distributors, and investors in the biosimilars market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.

Key Market Segments

Persistence Market Research’s report on the global biosimilars market offers information divided into four segments – product type, application, distribution channel, and region.

Product Type

Recombinant Glycosylated Proteins
Recombinant Non-Glycosylated Proteins
Application

Hematology
Growth Hormone Deficiency
Oncology
Diabetes Autoimmune
Disease
Others
Distribution Channel

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Region

North America
Latin America
Europe
South Asia and Pacific
East Asia
Middle East and Africa
Key Questions Answered in Study

Which region will hold the highest market share over the forecast period?
Which region is experiencing the highest growth (CAGR)?
Which factors are impacting the global biosimilars industry?
What are the global trends impacting the market?
What strategies must emerge players adopt to capture opportunities in various regions in the market?
What is the structure of the global biosimilars market?
Research Methodology

Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global biosimilars market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.

A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.

This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions - North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.

Our main sources of research include:

Primary Research
Secondary Research
Trade Research
Social Media Research



ページTOPに戻る


Table of Contents

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Technology Roadmap

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Product Adoption / Usage Analysis

4.2. Product USPs / Features

4.3. Strategic Promotional Strategies

5. Global Biosimilars Market Demand Analysis 2017–2021 and Forecast, 2022–2032

5.1. Historical Market Volume (Tons) Analysis, 2017–2021

5.2. Current and Future Market Volume (Tons) Projections, 2022–2032

5.3. Y-o-Y Growth Trend Analysis

6. Global Biosimilars Market - Pricing Analysis

6.1. Regional Pricing Analysis By Product Type

6.2. Global Average Pricing Analysis Benchmark

7. Global Biosimilars Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021

7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Market Background

8.1. Macro-Economic Factors

8.1.1. Global GDP Growth Outlook

8.1.2. Global Industry Value Added Overview

8.1.3. Global Infrastructure Investment Overview

8.1.4. Global Construction Spending Analysis

8.1.5. Other Macro Economic Factors

8.2. Forecast Factors - Relevance & Impact

8.2.1. Top Companies Historical Growth

8.2.2. GDP Growth forecast

8.2.3. Construction Industry forecast

8.2.4. Distribution Channel Growth Outlook

8.2.5. Collaboration Activities

8.3. Value Chain

8.3.1. Raw Material Suppliers

8.3.2. List of Manufacturers

8.3.3. List of Distributors

8.4. COVID-19 Crisis – Impact Assessment

8.4.1. Current Statistics

8.4.2. Short-Mid-Long Term Outlook

8.4.3. Likely Rebound

8.5. Market Dynamics

8.5.1. Drivers

8.5.2. Restraints

8.5.3. Opportunity Analysis

8.5.4. Trends

9. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Product Type

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021

9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Product Type 2022–2032

9.3.1. Recombinant Glycosylated Proteins

9.3.2. Recombinant Non-Glycosylated Proteins

9.4. Market Attractiveness Analysis by Product Type

10. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Application

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021

10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032

10.3.1. Hematology

10.3.2. Growth Hormone Deficiency

10.3.3. Oncology

10.3.4. Diabetes Autoimmune

10.3.5. Disease

10.3.6. Others

10.4. Market Attractiveness Analysis By Application

11. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

11.1. Introduction / Key Findings

11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021

11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032

11.3.1. Hospital Pharmacies

11.3.2. Online Pharmacies

11.3.3. Retail Pharmacies

11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032, by Region

12.1. Introduction

12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021

12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032

12.3.1. North America

12.3.2. Latin America

12.3.3. Europe

12.3.4. East Asia

12.3.5. South Asia and Pacific

12.3.6. Middle East and Africa (MEA)

12.4. Market Attractiveness Analysis By Region

13. North America Biosimilars Market Analysis 2017–2021 and Forecast 2022–2032

13.1. Introduction

13.2. Pricing Analysis

13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032

13.4.1. By Country

13.4.1.1. U.S.

13.4.1.2. Canada

13.4.2. By Type

13.4.3. By Application

13.4.4. By Distribution Channel

13.5. Market Attractiveness Analysis

13.5.1. By Country

13.5.2. By Type

13.5.3. By Application

13.5.4. By Distribution Channel

13.6. Market Trends

13.7. Key Market Participants - Intensity Mapping

13.8. Drivers and Restraints - Impact Analysis

14. Latin America Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

14.1. Introduction

14.2. Pricing Analysis

14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

14.4.1. By Country

14.4.1.1. Brazil

14.4.1.2. Mexico

14.4.1.3. Rest of Latin America

14.4.2. By Type

14.4.3. By Application

14.4.4. By Distribution Channel

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Type

14.5.3. By Application

14.5.4. By Distribution Channel

14.6. Market Trends

14.7. Key Market Participants - Intensity Mapping

14.8. Drivers and Restraints - Impact Analysis

15. Europe Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

15.1. Introduction

15.2. Pricing Analysis

15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021

15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

15.4.1. By Country

15.4.1.1. Germany

15.4.1.2. Italy

15.4.1.3. France

15.4.1.4. U.K.

15.4.1.5. Spain

15.4.1.6. BENELUX

15.4.1.7. Russia

15.4.1.8. Rest of Europe

15.4.2. By Type

15.4.3. By Application

15.4.4. By Distribution Channel

15.5. Market Attractiveness Analysis

15.5.1. By Country

15.5.2. By Type

15.5.3. By Application

15.5.4. By Distribution Channel

15.6. Market Trends

15.7. Key Market Participants - Intensity Mapping

15.8. Drivers and Restraints - Impact Analysis

16. South Asia and Pacific Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

16.1. Introduction

16.2. Pricing Analysis

16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

16.4.1. By Country

16.4.1.1. India

16.4.1.2. ASEAN

16.4.1.3. Oceania

16.4.1.4. Rest of South Asia & Pacific

16.4.2. By Type

16.4.3. By Application

16.4.4. By Distribution Channel

16.5. Market Attractiveness Analysis

16.5.1. By Country

16.5.2. By Type

16.5.3. By Application

16.5.4. By Distribution Channel

16.6. Market Trends

16.7. Key Market Participants - Intensity Mapping

16.8. Drivers and Restraints - Impact Analysis

17. East Asia Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

17.1. Introduction

17.2. Pricing Analysis

17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

17.4.1. By Country

17.4.1.1. China

17.4.1.2. Japan

17.4.1.3. South Korea

17.4.2. By Type

17.4.3. By Application

17.4.4. By Distribution Channel

17.5. Market Attractiveness Analysis

17.5.1. By Country

17.5.2. By Type

17.5.3. By Application

17.5.4. By Distribution Channel

17.6. Market Trends

17.7. Key Market Participants - Intensity Mapping

17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Biosimilars Market Analysis 2017-2021 and Forecast 2022-2032

18.1. Introduction

18.2. Pricing Analysis

18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

18.4.1. By Country

18.4.1.1. GCC Countries

18.4.1.2. Turkey

18.4.1.3. Northern Africa

18.4.1.4. South Africa

18.4.1.5. Rest of Middle East and Africa

18.4.2. By Type

18.4.3. By Application

18.4.4. By Distribution Channel

18.5. Market Attractiveness Analysis

18.5.1. By Country

18.5.2. By Type

18.5.3. By Application

18.5.4. By Distribution Channel

18.6. Market Trends

18.7. Key Market Participants - Intensity Mapping

18.8. Drivers and Restraints - Impact Analysis

19. Emerging Countries Biosimilars Market Analysis

19.1. Introduction

19.1.1. Market Value Proportion Analysis, By Key Countries

19.1.2. Global Vs. Country Growth Comparison

19.2. U.S. Biosimilars Market Analysis

19.2.1. By Type

19.2.2. By Application

19.2.3. By Distribution Channel

19.3. Canada Biosimilars Market Analysis

19.3.1. By Type

19.3.2. By Application

19.3.3. By Distribution Channel

19.4. Mexico Biosimilars Market Analysis

19.4.1. By Type

19.4.2. By Application

19.4.3. By Distribution Channel

19.5. Brazil Biosimilars Market Analysis

19.5.1. By Type

19.5.2. By Application

19.5.3. By Distribution Channel

19.6. Germany Biosimilars Market Analysis

19.6.1. By Type

19.6.2. By Application

19.6.3. By Distribution Channel

19.7. Italy Biosimilars Market Analysis

19.7.1. By Type

19.7.2. By Application

19.7.3. By Distribution Channel

19.8. France Biosimilars Market Analysis

19.8.1. By Type

19.8.2. By Application

19.8.3. By Distribution Channel

19.9. U.K. Biosimilars Market Analysis

19.9.1. By Type

19.9.2. By Application

19.9.3. By Distribution Channel

19.10. Spain Biosimilars Market Analysis

19.10.1. By Type

19.10.2. By Application

19.10.3. By Distribution Channel

19.11. BENELUX Biosimilars Market Analysis

19.11.1. By Type

19.11.2. By Application

19.11.3. By Distribution Channel

19.12. Russia Biosimilars Market Analysis

19.12.1. By Type

19.12.2. By Application

19.12.3. By Distribution Channel

19.13. China Biosimilars Market Analysis

19.13.1. By Type

19.13.2. By Application

19.13.3. By Distribution Channel

19.14. Japan Biosimilars Market Analysis

19.14.1. By Type

19.14.2. By Application

19.14.3. By Distribution Channel

19.15. S. Korea Biosimilars Market Analysis

19.15.1. By Type

19.15.2. By Application

19.15.3. By Distribution Channel

19.16. India Biosimilars Market Analysis

19.16.1. By Type

19.16.2. By Application

19.16.3. By Distribution Channel

19.17. ASEAN Biosimilars Market Analysis

19.17.1. By Type

19.17.2. By Application

19.17.3. By Distribution Channel

19.18. Australia and New Zealand Biosimilars Market Analysis

19.18.1. By Type

19.18.2. By Application

19.18.3. By Distribution Channel

19.19. GCC Countries Biosimilars Market Analysis

19.19.1. By Type

19.19.2. By Application

19.19.3. By Distribution Channel

19.20. Turkey Biosimilars Market Analysis

19.20.1. By Type

19.20.2. By Application

19.20.3. By Distribution Channel

19.21. Northern Africa Biosimilars Market Analysis

19.21.1. By Type

19.21.2. By Application

19.21.3. By Distribution Channel

19.22. South Africa Biosimilars Market Analysis

19.22.1. By Type

19.22.2. By Application

19.22.3. By Distribution Channel

20. Market Structure Analysis

20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)

20.2. Market Share Analysis of Top Players

20.3. Market Presence Analysis

21. Competition Analysis

21.1. Competition Dashboard

21.2. Competition Benchmarking

21.3. Competition Deep Dive

21.3.1. Pfizer Inc.

21.3.1.1. Overview

21.3.1.2. Product Portfolio

21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

21.3.1.4. Sales Footprint

21.3.1.5. Strategy Overview

21.3.2. Sandoz International GMBH

21.3.2.1. Overview

21.3.2.2. Product Portfolio

21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

21.3.2.4. Sales Footprint

21.3.2.5. Strategy Overview

21.3.3. Eli Lily & Company

21.3.3.1. Overview

21.3.3.2. Product Portfolio

21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

21.3.3.4. Sales Footprint

21.3.3.5. Strategy Overview

21.3.4. Hospira Inc.

21.3.4.1. Overview

21.3.4.2. Product Portfolio

21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

21.3.4.4. Sales Footprint

21.3.4.5. Strategy Overview

21.3.5. Amgen, Inc.

21.3.5.1. Overview

21.3.5.2. Product Portfolio

21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

21.3.5.4. Sales Footprint

21.3.5.5. Strategy Overview

21.3.6. Biocon Ltd.

21.3.6.1. Overview

21.3.6.2. Product Portfolio

21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

21.3.6.4. Sales Footprint

21.3.6.5. Strategy Overview

21.3.7. Actavis, Inc.

21.3.7.1. Overview

21.3.7.2. Product Portfolio

21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

21.3.7.4. Sales Footprint

21.3.7.5. Strategy Overview

21.3.8. Cipla Ltd.

21.3.8.1. Overview

21.3.8.2. Product Portfolio

21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

21.3.8.4. Sales Footprint

21.3.8.5. Strategy Overview

21.3.9. Teva Pharmaceutical Industries, Ltd.

21.3.9.1. Overview

21.3.9.2. Product Portfolio

21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

21.3.9.4. Sales Footprint

21.3.9.5. Strategy Overview

21.3.10. Dr. Reddy’s Laboratories Ltd.

21.3.10.1. Overview

21.3.10.2. Product Portfolio

21.3.10.3. Profitability by Market Segments (Product/Channel/Region)

21.3.10.4. Sales Footprint

21.3.10.5. Strategy Overview

21.3.11. Celltrion, Inc.

21.3.11.1. Overview

21.3.11.2. Product Portfolio

21.3.11.3. Profitability by Market Segments (Product/Channel/Region)

21.3.11.4. Sales Footprint

21.3.11.5. Strategy Overview

21.3.12. Stada Arzeimittel Ag

21.3.12.1. Overview

21.3.12.2. Product Portfolio

21.3.12.3. Profitability by Market Segments (Product/Channel/Region)

21.3.12.4. Sales Footprint

21.3.12.5. Strategy Overview

21.3.13. Mylan, Inc.

21.3.13.1. Overview

21.3.13.2. Product Portfolio

21.3.13.3. Profitability by Market Segments (Product/Channel/Region)

21.3.13.4. Sales Footprint

21.3.13.5. Strategy Overview

21.3.14. Wockhardt Ltd.

21.3.14.1. Overview

21.3.14.2. Product Portfolio

21.3.14.3. Profitability by Market Segments (Product/Channel/Region)

21.3.14.4. Sales Footprint

21.3.14.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート


よくあるご質問


Persistence Market Research社はどのような調査会社ですか?


パーシスタンスマーケットリサーチ(Persistence Market Research/PMR)は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/07/04 10:27

162.47 円

175.74 円

209.86 円

ページTOPに戻る